PTCT vs. LRN

Last updated Jun 4, 2026

PTCT (PTC Therapeutics, Inc.) and LRN (Stride, Inc.) are both stocks. PTCT operates in Biotechnology (Healthcare), while LRN operates in Education & Training Services (Consumer Defensive). Over the past 10 years, PTCT returned 24.54%/yr vs 23.78%/yr for LRN. At a 0.20 correlation, their price movements are largely independent.

Performance

PTCT vs. LRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in PTC Therapeutics, Inc. (PTCT) and Stride, Inc. (LRN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PTCT achieves a -9.58% return, which is significantly lower than LRN's 53.44% return. Both investments have delivered pretty close results over the past 10 years, with PTCT having a 24.54% annualized return and LRN not far behind at 23.78%.

PTCT

• 1D: 0.66%
• 1M: 4.87%
• YTD: -9.58%
• 6M: -9.35%
• 1Y: 35.49%
• 3Y*: 15.90%
• 5Y*: 11.88%
• 10Y*: 24.54%

LRN

• 1D: 1.76%
• 1M: 7.99%
• YTD: 53.44%
• 6M: 62.77%
• 1Y: -30.11%
• 3Y*: 33.48%
• 5Y*: 28.19%
• 10Y*: 23.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

PTCT vs. LRN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PTCT PTC Therapeutics, Inc.	-9.58%	68.28%	63.79%	-27.80%	-4.17%	-34.74%	27.07%	39.95%	105.76%	52.89%
LRN Stride, Inc.	53.44%	-37.53%	75.05%	89.80%	-6.15%	56.99%	4.32%	-17.91%	55.91%	-7.34%

Correlation

The correlation between PTCT and LRN is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.16
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (10Y) Calculated over the trailing 10-year period	0.19
Correlation (All Time) Calculated using the full available price history since Jun 21, 2013	0.20

The correlation between PTCT and LRN shifts across timeframes, from 0.07 (1 year) to 0.20 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap PTCT : $5.67B LRN : $4.74B
EPS PTCT : -$2.27 LRN : $9.68
PS Ratio PTCT : 6.82 LRN : 1.90
Total Revenue (TTM) PTCT : $827.11M LRN : $2.54B
Gross Profit (TTM) PTCT : $410.90M LRN : $972.24M
EBITDA (TTM) PTCT : -$38.52M LRN : $424.60M

Return for Risk

PTCT vs. LRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PTCT

PTCT Risk / Return Rank: 66
PTCT Sharpe Ratio Rank: 69
PTCT Sortino Ratio Rank: 65
PTCT Omega Ratio Rank: 64
PTCT Calmar Ratio Rank: 67
PTCT Martin Ratio Rank: 65

LRN

LRN Risk / Return Rank: 25
LRN Sharpe Ratio Rank: 21
LRN Sortino Ratio Rank: 27
LRN Omega Ratio Rank: 26
LRN Calmar Ratio Rank: 25
LRN Martin Ratio Rank: 27

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PTCT vs. LRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for PTC Therapeutics, Inc. (PTCT) and Stride, Inc. (LRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PTCT	LRN	Difference
Sharpe ratio Return per unit of total volatility	0.86	-0.45	+1.31
Sortino ratio Return per unit of downside risk	1.49	-0.08	+1.56
Omega ratio Gain probability vs. loss probability	1.19	0.98	+0.21
Calmar ratio Return relative to maximum drawdown	1.31	-0.47	+1.78
Martin ratio Return relative to average drawdown	2.72	-0.73	+3.44
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PTCT vs. LRN - Sharpe Ratio Comparison

The current PTCT Sharpe Ratio is 0.86, which is higher than the LRN Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of PTCT and LRN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	PTCT	LRN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.86	-0.45	+1.31
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.22	0.55	-0.33
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.37	0.48	-0.11
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.15	+0.01

Drawdowns

PTCT vs. LRN - Drawdown Comparison

The maximum PTCT drawdown since its inception was -94.60%, which is greater than LRN's maximum drawdown of -81.41%. Use the drawdown chart below to compare losses from any high point for PTCT and LRN.

Drawdown Indicators

	PTCT	LRN	Difference
Max Drawdown Largest peak-to-trough decline	-94.60%	-81.41%	-13.19%
Max Drawdown (1Y) Largest decline over 1 year	-27.17%	-64.07%	+36.90%
Max Drawdown (3Y) Largest decline over 3 years	-59.86%	-64.07%	+4.21%
Max Drawdown (5Y) Largest decline over 5 years	-69.42%	-64.07%	-5.35%
Max Drawdown (10Y) Largest decline over 10 years	-73.78%	-64.07%	-9.71%
Current Drawdown Current decline from peak	-20.37%	-41.33%	+20.96%
Average Drawdown Average peak-to-trough decline	-46.09%	-36.27%	-9.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.09%	41.53%	-28.44%

Volatility

PTCT vs. LRN - Volatility Comparison

PTC Therapeutics, Inc. (PTCT) has a higher volatility of 18.71% compared to Stride, Inc. (LRN) at 7.85%. This indicates that PTCT's price experiences larger fluctuations and is considered to be riskier than LRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PTCT	LRN	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.71%	7.85%	+10.86%
Volatility (6M) Calculated over the trailing 6-month period	29.23%	23.81%	+5.42%
Volatility (1Y) Calculated over the trailing 1-year period	41.80%	67.31%	-25.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	54.86%	51.38%	+3.48%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	66.56%	49.23%	+17.33%

Dividends

PTCT vs. LRN - Dividend Comparison

Neither PTCT nor LRN has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

PTCT vs. LRN - Profitability Comparison

The chart below illustrates the profitability comparison between PTC Therapeutics, Inc. and Stride, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PTCT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, PTC Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 272.55M. Therefore, the gross margin over that period was 0.0%.

LRN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Stride, Inc. reported a gross profit of 231.56M and revenue of 629.87M. Therefore, the gross margin over that period was 36.8%.

PTCT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, PTC Therapeutics, Inc. reported an operating income of 44.96M and revenue of 272.55M, resulting in an operating margin of 16.5%.

LRN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Stride, Inc. reported an operating income of 129.08M and revenue of 629.87M, resulting in an operating margin of 20.5%.

PTCT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, PTC Therapeutics, Inc. reported a net income of -2.81M and revenue of 272.55M, resulting in a net margin of -1.0%.

LRN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Stride, Inc. reported a net income of 248.49M and revenue of 629.87M, resulting in a net margin of 39.5%.

Frequently Asked Questions

Can I hold both PTCT and LRN in my portfolio?

PTCT and LRN have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PTCT or LRN?

PTCT has higher volatility (18.71%) compared to LRN (7.85%). In terms of maximum drawdown, PTCT dropped -94.60% vs LRN's -81.41%.

Which has better risk-adjusted returns?

PTCT currently has the higher Sharpe Ratio (0.86 vs -0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.